315 related articles for article (PubMed ID: 29444940)
1. Dynamics of Evolution of Poliovirus Neutralizing Antigenic Sites and Other Capsid Functional Domains during a Large and Prolonged Outbreak.
Shaw J; Jorba J; Zhao K; Iber J; Chen Q; Adu F; Adeniji A; Bukbuk D; Baba M; Henderson E; Dybdahl-Sissoko N; McDonald S; Weldon WC; Gumede N; Oberste MS; Kew OM; Burns CC
J Virol; 2018 May; 92(9):. PubMed ID: 29444940
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1.
Blomqvist S; Bruu AL; Stenvik M; Hovi T
J Gen Virol; 2003 Mar; 84(Pt 3):573-580. PubMed ID: 12604808
[TBL] [Abstract][Full Text] [Related]
3. Antigenic structure of polioviruses of serotypes 1, 2 and 3.
Minor PD; Ferguson M; Evans DM; Almond JW; Icenogle JP
J Gen Virol; 1986 Jul; 67 ( Pt 7)():1283-91. PubMed ID: 2425046
[TBL] [Abstract][Full Text] [Related]
4. Evolution of poliovirus during an outbreak: sequential type 3 poliovirus isolates from several persons show shifts of neutralization determinants.
Huovilainen A; Hovi T; Kinnunen L; Takkinen K; Ferguson M; Minor P
J Gen Virol; 1987 May; 68 ( Pt 5)():1373-8. PubMed ID: 2437244
[TBL] [Abstract][Full Text] [Related]
5. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria.
Burns CC; Shaw J; Jorba J; Bukbuk D; Adu F; Gumede N; Pate MA; Abanida EA; Gasasira A; Iber J; Chen Q; Vincent A; Chenoweth P; Henderson E; Wannemuehler K; Naeem A; Umami RN; Nishimura Y; Shimizu H; Baba M; Adeniji A; Williams AJ; Kilpatrick DR; Oberste MS; Wassilak SG; Tomori O; Pallansch MA; Kew O
J Virol; 2013 May; 87(9):4907-22. PubMed ID: 23408630
[TBL] [Abstract][Full Text] [Related]
6. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
[TBL] [Abstract][Full Text] [Related]
7. Long-term excretion of vaccine-derived poliovirus by a healthy child.
Martín J; Odoom K; Tuite G; Dunn G; Hopewell N; Cooper G; Fitzharris C; Butler K; Hall WW; Minor PD
J Virol; 2004 Dec; 78(24):13839-47. PubMed ID: 15564492
[TBL] [Abstract][Full Text] [Related]
8. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.
Blondel B; Crainic R; Fichot O; Dufraisse G; Candrea A; Diamond D; Girard M; Horaud F
J Virol; 1986 Jan; 57(1):81-90. PubMed ID: 2416957
[TBL] [Abstract][Full Text] [Related]
9. Nucleotide sequences of the VP1 capsid proteins of wild poliovirus types 1 and 3 from epidemic areas of Brazil.
Da-Silva EE; Schatzmayr HG; Kew OM
Braz J Med Biol Res; 1990; 23(1):1-5. PubMed ID: 2167137
[TBL] [Abstract][Full Text] [Related]
10. Mapping of antigenic domains in poliovirus VP1 involved in structural rearrangements during virus morphogenesis and antigenic alterations of the virion.
Ketterlinus R; Wiegers K
Virology; 1994 Oct; 204(1):27-37. PubMed ID: 7522372
[TBL] [Abstract][Full Text] [Related]
11. Determining the epitope dominance on the capsid of a serotype SAT2 foot-and-mouth disease virus by mutational analyses.
Opperman PA; Rotherham LS; Esterhuysen J; Charleston B; Juleff N; Capozzo AV; Theron J; Maree FF
J Virol; 2014 Aug; 88(15):8307-18. PubMed ID: 24829347
[TBL] [Abstract][Full Text] [Related]
12. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
[TBL] [Abstract][Full Text] [Related]
13. Cleavage of VP1 and modification of antigenic site 1 of type 2 polioviruses by intestinal trypsin.
Roivainen M; Hovi T
J Virol; 1988 Sep; 62(9):3536-9. PubMed ID: 2841503
[TBL] [Abstract][Full Text] [Related]
14. A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly Diverged Sabin 2 Vaccine Poliovirus.
Korotkova EA; Gmyl AP; Yakovenko ML; Ivanova OE; Eremeeva TP; Kozlovskaya LI; Shakaryan AK; Lipskaya GY; Parshina IL; Loginovskikh NV; Morozova NS; Agol VI
J Virol; 2016 Jul; 90(13):5978-88. PubMed ID: 27099315
[TBL] [Abstract][Full Text] [Related]
15. Determination of antigenic properties of vaccine derived poliovirus strains.
Pliaka V; Achilleos C; Kyriakopoulou Z; Tsakogiannis D; Ruether IG; Gartzonica C; Levidiotou-Stefanou S; Markoulatos P
Vaccine; 2010 Dec; 29(1):26-33. PubMed ID: 20974307
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test.
Arita M; Iwai-Itamochi M
Sci Rep; 2019 Aug; 9(1):11970. PubMed ID: 31427704
[TBL] [Abstract][Full Text] [Related]
17. Antigenic variation among 173 strains of type 3 poliovirus isolated in Finland during the 1984 to 1985 outbreak.
Huovilainen A; Kinnunen L; Ferguson M; Hovi T
J Gen Virol; 1988 Aug; 69 ( Pt 8)():1941-8. PubMed ID: 2841408
[TBL] [Abstract][Full Text] [Related]
18. Rare natural type 3/type 2 intertypic capsid recombinant vaccine-related poliovirus isolated from a case of acute flaccid paralysis in Brazil, 2015.
Cassemiro KMSM; Burlandy FM; da Silva EE
J Gen Virol; 2016 Jul; 97(7):1545-1550. PubMed ID: 27082658
[TBL] [Abstract][Full Text] [Related]
19. Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis.
Martín J; Samoilovich E; Dunn G; Lackenby A; Feldman E; Heath A; Svirchevskaya E; Cooper G; Yermalovich M; Minor PD
J Virol; 2002 Nov; 76(21):10921-8. PubMed ID: 12368335
[TBL] [Abstract][Full Text] [Related]
20. Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies.
Fiore L; Ridolfi B; Genovese D; Buttinelli G; Lucioli S; Lahm A; Ruggeri FM
J Virol; 1997 Sep; 71(9):6905-12. PubMed ID: 9261417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
